Treatment failure and resistance with direct‐acting antiviral drugs against hepatitis C virus
Jean‐Michel Pawlotsky – 3 March 2011 – Current treatment of chronic hepatitis C virus (HCV) infection is based on the combination of pegylated interferon‐α and ribavirin. The recent development of direct‐acting antiviral (DAA) molecules that are active on HCV, together with in vitro and in vivo studies showing that these drugs may lead to the selection of resistant viruses if administered alone, has raised concerns that resistance may undermine therapy based on DAAs.